Folic acid injection Rx
Generic Name and Formulations:
Folic acid 5mg/mL; soln for IV, IM or SC inj; contains benzyl alcohol and aluminum.
Various generic manufacturers
Indications for Folic acid injection:
Megaloblastic anemias of folic acid deficiency. Anemias of nutritional origin, pregnancy, infancy or childhood.
Adults and Children:
Usual dose: up to 1mg daily; may need higher dose if resistant disease. Maintenance: infants: 0.1mg/day; <4yrs: 0.3mg/day; ≥4yrs: 0.4mg/day. Pregnant or lactating: 0.8mg/day. Alcoholism, hemolytic anemia, anticonvulsant therapy or chronic infection: may require higher dose.
Use injectable form if disease is severe or GI absorption impaired. Rule out or treat vitamin B12 deficiency prior to treatment. May obscure diagnosis of pernicious anemia. Pregnancy (Cat. A).
May antagonize phenytoin. False low serum and red cell folate levels may occur with antibiotics (eg. tetracycline).
Formerly known under the brand names Folicet (tabs); Folvite (tabs, inj).
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States